Azienda Sanitaria Locale Della Provincia Di Barletta Andria Trani
- Address
- lock Available on a paid plan
Azienda Sanitaria Locale Della Provincia Di Barletta Andria Trani - Oncology and Hematology Research Center
This Italian healthcare institution demonstrates significant expertise in oncological and hematological malignancies, with a particular emphasis on lymphoma research and innovative treatment approaches. The center actively participates in multi-phase clinical trials exploring novel therapeutic combinations and organ-preserving strategies for cancer patients.
- Advanced lymphoma research including plasmablastic lymphoma, diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma, and follicular lymphoma with innovative immunotherapy combinations
- Colorectal cancer studies focusing on organ-sparing techniques using electrochemotherapy after neoadjuvant treatment
- Musculoskeletal disorders research, specifically knee osteoarthritis treatment with intra-articular therapies
The center's research portfolio reflects a commitment to personalized medicine approaches and addresses complex patient populations, including elderly patients with aggressive lymphomas and those with relapsed or refractory disease. Their involvement in phase I through phase III trials demonstrates comprehensive capabilities in drug development and evaluation, with particular focus on immunotherapy combinations, targeted therapies using agents like daratumumab and atezolizumab, and innovative treatment modalities for both hematologic and solid tumors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Fondazione Italiana Linfomi Ets2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Italiana Linfomi Ets3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Della Provincia Di Barletta Andria Trani
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2023-02-27 | 2023-02-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.